Skip to main content

Jasper Therapeutics, Inc.

JSPR
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001788028

No open-market purchases or sales by Jasper Therapeutics, Inc. insiders were filed in the last 90 days; 52 institutions reported holding it in 13F filings for Q3 2026, worth $8.77M in total; no superinvestor holds it.

Currency
USD
Source
SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
Updated
Nov 17, 2026, 2:22 AM ET

Income statement

Each column is one fiscal year, newest first.

Income statement of Jasper Therapeutics, Inc., annual
Line itemFY2025FY2024FY2023FY2022FY2021
Period endDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021
Filing10-K10-K10-K10-K10-K
ReportedMar 30, 2026Feb 27, 2025Mar 4, 2024Mar 8, 2023Mar 18, 2022
Cost of revenue$41.6M––––
Operating expenses$83.9M$76.2M$68.9M$51.2M$36.8M
Research and development$63.1M$55.8M$51.8M$34.6M$25.4M
Selling, general and administrative$20.8M$20.4M$17.1M$16.6M$11.4M
Operating income-$83.9M-$76.2M-$68.9M-$51.2M-$36.8M
Income tax–$2.00K–––
Net income-$75.8M-$71.3M-$64.5M-$37.7M-$30.6M
EPS, basic$-3.95$-4.89$-6.18$-1.03–
EPS, diluted$-3.95$-4.89$-6.18$-1.03–
Weighted shares, basic19.2M14.6M10.4M36.5M–
Weighted shares, diluted19.2M14.6M10.4M36.5M–

Balance sheet

Each column is one fiscal year, newest first.

Balance sheet of Jasper Therapeutics, Inc., annual
Line itemFY2025FY2024FY2023FY2022FY2021
Period endDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021
Filing10-K10-K10-K10-K10-K
ReportedMar 30, 2026Feb 27, 2025Mar 4, 2024Mar 8, 2023Mar 18, 2022
Cash and equivalents$28.7M$71.6M$86.9M$38.3M$84.7M
Total current assets$34.6M$75.8M$88.9M$41.7M$87.8M
Property, plant and equipment$102.0K$1.88M$2.73M$3.57M$3.69M
Total assets$35.8M$79.9M$94.9M$48.4M$93.7M
Accounts payable$6.22M$4.03M$4.15M$1.77M$3.92M
Total current liabilities$13.2M$15.2M$12.4M$7.07M$8.02M
Total liabilities$31.6M$18.2M$16.5M$12.4M$24.1M
Shareholders' equity$4.15M$61.7M$78.4M$36.0M$69.5M

Cash flow statement

Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.

Cash flow statement of Jasper Therapeutics, Inc., annual
Line itemFY2025FY2024FY2023FY2022FY2021
Period endDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021
Filing10-K10-K10-K10-K10-K
ReportedMar 30, 2026Feb 27, 2025Mar 4, 2024Mar 8, 2023Mar 18, 2022
Operating cash flow-$77.2M-$62.6M-$52.1M-$45.9M-$33.7M
Depreciation and amortization$1.06M$1.37M$1.11M$975.0K$377.0K
Stock-based compensation$6.71M$6.62M$5.21M$4.09M$1.05M
Investing cash flow$5.00K-$532.0K-$267.0K-$576.0K-$2.43M
Financing cash flow$34.2M$47.9M$101.0M$55.0K$101.0M

Shares outstanding

Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.

Shares outstanding for Jasper Therapeutics, Inc. by cover date
Cover dateShares outstandingChange in a yearFiling
Nov 10, 20261.11M−96.0%SEC
Aug 10, 202633.3M+104.7%SEC
May 11, 202628.0M+86.4%SEC
Mar 25, 202628.0M+86.4%SEC
Nov 6, 202528.0M–SEC
Aug 11, 202516.3M–SEC
May 8, 202515.0M–SEC
Feb 25, 202515.0M–SEC

Notes and known gaps

How these numbers are put together, and what they can't tell you.

  • Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
  • Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.

Known gaps

  • Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
  • EPS and share counts are as reported at the time, not adjusted for later stock splits.
  • For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
  • For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
  • Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
  • Depreciation and amortization is missing for some companies that report it under their own XBRL tags.